FIGURE 7.

In vivo anti-tumor effects of combination treatment with HER-2 l-amino acid peptide. Wild type BALB/c mice (n = 5), at the age of 5–6 weeks, were challenged with TUBO cells that were derived from BALB-neuT mice which are transgenic for the rat HER-2/neu oncogene and were treated intravenously with HER-2 and VEGF peptide mimics and scrambled irrelevant peptide. Tumor measurements were performed twice a week using calipers. The data are presented as the average tumor size per group and are reported as 3 mm for combination treatment with HER-2 l-amino acid VEGF peptide mimics.